JP2023550446A - 抗ｃｄ２５抗体 - Google Patents

抗ｃｄ２５抗体 Download PDF

Info

Publication number
JP2023550446A
JP2023550446A JP2023530329A JP2023530329A JP2023550446A JP 2023550446 A JP2023550446 A JP 2023550446A JP 2023530329 A JP2023530329 A JP 2023530329A JP 2023530329 A JP2023530329 A JP 2023530329A JP 2023550446 A JP2023550446 A JP 2023550446A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
binding fragment
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550446A5 (enExample
Inventor
オリーブ，ダニエル
ベンスーサン，アルマンド
ジュスティニアーニ，ジェローム
マリー－カルディネ，アン
フォウスサット，アルノー
ウアシーヌ，ジェミラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Paris Cite
Original Assignee
Universite Paris Cite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Paris Cite filed Critical Universite Paris Cite
Publication of JP2023550446A publication Critical patent/JP2023550446A/ja
Publication of JP2023550446A5 publication Critical patent/JP2023550446A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023530329A 2020-11-20 2021-11-19 抗ｃｄ２５抗体 Pending JP2023550446A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20306424 2020-11-20
EP20306424.1 2020-11-20
PCT/EP2021/082383 WO2022106665A1 (en) 2020-11-20 2021-11-19 Anti-cd25 antibodies

Publications (2)

Publication Number Publication Date
JP2023550446A true JP2023550446A (ja) 2023-12-01
JP2023550446A5 JP2023550446A5 (enExample) 2024-11-25

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530329A Pending JP2023550446A (ja) 2020-11-20 2021-11-19 抗ｃｄ２５抗体

Country Status (9)

Country Link
US (1) US20240002522A1 (enExample)
EP (1) EP4247497A1 (enExample)
JP (1) JP2023550446A (enExample)
KR (1) KR20230118108A (enExample)
CN (1) CN116917318A (enExample)
AR (1) AR124123A1 (enExample)
AU (1) AU2021380966A1 (enExample)
CA (1) CA3199006A1 (enExample)
WO (1) WO2022106665A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019175222A1 (en) * 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
JP2020514363A (ja) * 2017-03-17 2020-05-21 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
JP2020525517A (ja) * 2017-07-06 2020-08-27 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための化合物及び方法
WO2020234399A1 (en) * 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020514363A (ja) * 2017-03-17 2020-05-21 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のためのＦｃ最適化抗ＣＤ２５
JP2020525517A (ja) * 2017-07-06 2020-08-27 タスク セラピューティクス リミテッド 腫瘍特異的細胞枯渇のための化合物及び方法
WO2019175222A1 (en) * 2018-03-13 2019-09-19 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
WO2020234399A1 (en) * 2019-05-20 2020-11-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel anti-cd25 antibodies

Also Published As

Publication number Publication date
CA3199006A1 (en) 2022-05-27
CN116917318A (zh) 2023-10-20
EP4247497A1 (en) 2023-09-27
KR20230118108A (ko) 2023-08-10
US20240002522A1 (en) 2024-01-04
AU2021380966A1 (en) 2023-06-22
AR124123A1 (es) 2023-02-15
WO2022106665A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
US12415854B2 (en) Antibodies to TIGIT
JP7728822B2 (ja) キメラ抗原受容体及びｔ細胞受容体並びに使用方法
JP7702874B2 (ja) Ｄｌｌ３標的化キメラ抗原受容体および結合剤
JP7834028B2 (ja) Ｉｌｔ結合剤及びその使用方法
US20220251232A1 (en) Novel anti-cd25 antibodies
AU2021236302A1 (en) Novel anti-LILRB4 antibodies and derivative products
KR20190095919A (ko) 항-인간 4-1bb 항체 및 그의 용도
JP2024504547A (ja) 抗ｃｄ２５抗体
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
JP2023550446A (ja) 抗ｃｄ２５抗体
WO2024163530A2 (en) Novel anti-ccr4 antibodies and derivative products
CA3176246C (en) Antibodies to tigit
US20240382592A1 (en) Methods for the treatment of anaplastic large cell lymphoma
WO2023143478A1 (en) Novel anti-cd4 and anti-pd-l1 bispecific antibodies
TWI917318B (zh) 靶向ｄｌｌ３的嵌合抗原受體和結合劑
WO2023222886A1 (en) Antibody-cytokine fusion proteins
TW202528358A (zh) 利用結合至epcam及cd137之藥劑與pd-1軸結合拮抗劑組合的治療方法
HK40088961A (zh) 抗tigit抗体
EA049282B1 (ru) Антитела к tigit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260423